Literature DB >> 17991352

Current treatment and management of retinoblastoma.

Dan S Gombos1, And Patricia Chevez-Barrios.   

Abstract

Retinoblastoma was traditionally treated with enucleation and external-beam radiotherapy. However, in the past decade, systemic chemotherapy has become the primary globe-salvaging approach. This approach is generally combined with focal treatment, allowing for tumor consolidation following initial chemoreduction. A recently developed classification scheme may improve our ability to predict outcomes with this treatment modality. The Children's Oncology Group has initiated a series of prospective multicenter trials to improve treatment outcomes with systemic chemotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17991352     DOI: 10.1007/s11912-007-0063-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  33 in total

1.  A new era for the treatment of retinoblastoma.

Authors:  F L Ferris; E Y Chew
Journal:  Arch Ophthalmol       Date:  1996-11

Review 2.  Retinoblastoma: clinical and histopathologic features.

Authors:  D N Sang; D M Albert
Journal:  Hum Pathol       Date:  1982-02       Impact factor: 3.466

Review 3.  Intraocular retinoblastoma: the case for a new group classification.

Authors:  A Linn Murphree
Journal:  Ophthalmol Clin North Am       Date:  2005-03

4.  Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.

Authors:  C L Shields; J A Shields; M Needle; P de Potter; S Kheterpal; A Hamada; A T Meadows
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

5.  Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk.

Authors:  D H Abramson; C M Frank
Journal:  Ophthalmology       Date:  1998-04       Impact factor: 12.079

6.  Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma).

Authors:  C L Shields; A T Meadows; J A Shields; C Carvalho; A F Smith
Journal:  Arch Ophthalmol       Date:  2001-09

Review 7.  Leukemias related to treatment with DNA topoisomerase II inhibitors.

Authors:  C A Felix
Journal:  Med Pediatr Oncol       Date:  2001-05

8.  Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K Baez; J R Cater; P De Potter
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

Review 9.  Trilateral retinoblastoma: insights into histogenesis and management.

Authors:  D M Marcus; S E Brooks; G Leff; R McCormick; T Thompson; S Anfinson; J Lasudry; D M Albert
Journal:  Surv Ophthalmol       Date:  1998 Jul-Aug       Impact factor: 6.048

10.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.

Authors:  N J Winick; R W McKenna; J J Shuster; N R Schneider; M J Borowitz; W P Bowman; D Jacaruso; B A Kamen; G R Buchanan
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

View more
  5 in total

1.  Changing causes of enucleation over the past 60 years.

Authors:  Vikram J Setlur; Jignesh G Parikh; Narsing A Rao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-17       Impact factor: 3.117

2.  Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience.

Authors:  Hyery Kim; Ji Won Lee; Hyoung Jin Kang; Hyeon Jin Park; Yoon Yi Kim; Hee Young Shin; Young Suk Yu; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

3.  Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/β-catenin pathway.

Authors:  Yali Gao; Xiaohe Lu
Journal:  Tumour Biol       Date:  2015-12-10

4.  Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model.

Authors:  A D Kulkarni; P R van Ginkel; S R Darjatmoko; M J Lindstrom; D M Albert
Journal:  Br J Ophthalmol       Date:  2009-03-30       Impact factor: 4.638

5.  Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.

Authors:  Wei-Ting Hsiao; Ming-Dar Tsai; Guey-Mei Jow; Lu-Tai Tien; Yih-Jing Lee
Journal:  Mol Vis       Date:  2012-07-20       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.